American Association for Cancer Research
Browse
00085472can170049-sup-176995_2_supp_4159899_ct2c0k.pdf (136.81 kB)

Table S1 to S3 from Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis

Download (136.81 kB)
journal contribution
posted on 2023-03-31, 00:43 authored by Yun-Chi Tang, Hui Yuwen, Kaiying Wang, Peter M. Bruno, Kevin Bullock, Amy Deik, Stefano Santaguida, Marianna Trakala, Sarah J. Pfau, Na Zhong, Tao Huang, Lan Wang, Clary B. Clish, Michael T. Hemann, Angelika Amon

Table S1: Summary of compound effect in aneuploid Ts13 MEF compared to euploid wild-type MEF. Table S2: shRNA and siRNA sequences used in this study. Table S3: Primers used for quantitative Real-Time PCR.

Funding

National Key Research and Development Program of China

Strategic Priority Research Program of the Chinese Academy of Sciences

General Program of National Natural Science Foundation of China

National Thousand Talents

Ludwig Institute for Cancer Research

Howard Hughes Medical Institute

AICF

EMBO

History

ARTICLE ABSTRACT

Aneuploidy, a hallmark of cancer cells, poses an appealing opportunity for cancer treatment and prevention strategies. Using a cell-based screen to identify small molecules that could selectively kill aneuploid cells, we identified the compound N-[2-hydroxy-1-(4-morpholinylmethyl)-2-phenylethyl]-decanamide monohydrochloride (DL-PDMP), an antagonist of UDP-glucose ceramide glucosyltransferase. DL-PDMP selectively inhibited proliferation of aneuploid primary mouse embryonic fibroblasts and aneuploid colorectal cancer cells. Its selective cytotoxic effects were based on further accentuating the elevated levels of ceramide, which characterize aneuploid cells, leading to increased apoptosis. We observed that DL-PDMP could also enhance the cytotoxic effects of paclitaxel, a standard-of-care chemotherapeutic agent that causes aneuploidy, in human colon cancer and mouse lymphoma cells. Our results offer pharmacologic evidence that the aneuploid state in cancer cells can be targeted selectively for therapeutic purposes, or for reducing the toxicity of taxane-based drug regimens. Cancer Res; 77(19); 5272–86. ©2017 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC